Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
Andrea Rinaldi, Ivo Kwee, Monica Taborelli, et al.
British Journal of Haematology (2005) Vol. 132, Iss. 3, pp. 303-316
Closed Access | Times Cited: 194

Showing 26-50 of 194 citing articles:

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
Shuang Q. Zhang, Sonali M. Smith, Shuang Y. Zhang, et al.
British Journal of Haematology (2015) Vol. 170, Iss. 4, pp. 445-456
Open Access | Times Cited: 86
Characterization of ibrutinib‐sensitive and ‐resistant mantle lymphoma cells
Jiao Ma, Pin Lu, Ailin Guo, et al.
British Journal of Haematology (2014) Vol. 166, Iss. 6, pp. 849-861
Closed Access | Times Cited: 83
Targeting the B cell receptor pathway in chronic lymphocytic leukemia
Matthew S. Davids, Jennifer R. Brown
Leukemia & lymphoma/Leukemia and lymphoma (2012) Vol. 53, Iss. 12, pp. 2362-2370
Open Access | Times Cited: 78
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
Jan de Jong, Juthamas Sukbuntherng, Donna Skee, et al.
Cancer Chemotherapy and Pharmacology (2015) Vol. 75, Iss. 5, pp. 907-916
Open Access | Times Cited: 67
Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
Amin Aalipour, Ranjana H. Advani
Therapeutic Advances in Hematology (2014) Vol. 5, Iss. 4, pp. 121-133
Open Access | Times Cited: 67
Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies
Dimitar G. Efremov, Sven Turkalj, Luca Laurenti
Cancers (2020) Vol. 12, Iss. 6, pp. 1396-1396
Open Access | Times Cited: 65
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
Y Li, Myriam N. Bouchlaka, Jared Wolff, et al.
Oncogene (2016) Vol. 35, Iss. 48, pp. 6223-6234
Open Access | Times Cited: 63
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Núria Profitós-Pelejà, Juliana C. Santos, Ana Marín‐Niebla, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 860-860
Open Access | Times Cited: 36
ConcomitantMYCand microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma
Andrea Rinaldi, Giulia Poretti, Ivo Kwee, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2007) Vol. 48, Iss. 2, pp. 410-412
Closed Access | Times Cited: 97
Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma
Blanca Espinet, Itziar Salaverría, Sı́lvia Beà, et al.
Genes Chromosomes and Cancer (2010) Vol. 49, Iss. 5, pp. 439-451
Closed Access | Times Cited: 85
Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis
Magda Pinyol, Sı́lvia Beà, Laura Plà, et al.
Blood (2007) Vol. 109, Iss. 12, pp. 5422-5429
Open Access | Times Cited: 82
Syk Tyrosine Kinase Is Linked to Cell Motility and Progression in Squamous Cell Carcinomas of the Head and Neck
Sutima Luangdilok, Carol Box, Lisa Patterson, et al.
Cancer Research (2007) Vol. 67, Iss. 16, pp. 7907-7916
Open Access | Times Cited: 82
Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling
Chiara Pighi, Ting‐Lei Gu, Irene Dalai, et al.
Cellular Oncology (2011) Vol. 34, Iss. 2, pp. 141-153
Open Access | Times Cited: 76
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
Amin Aalipour, Ranjana H. Advani
British Journal of Haematology (2013) Vol. 163, Iss. 4, pp. 436-443
Open Access | Times Cited: 71
B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies
Kamal D. Puri, Julie A. Di Paolo, Michael R. Gold
International Reviews of Immunology (2013) Vol. 32, Iss. 4, pp. 397-427
Closed Access | Times Cited: 64
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma
Paola Bonetti, Monica Testoni, Marta Scandurra, et al.
Blood (2013) Vol. 122, Iss. 13, pp. 2233-2241
Open Access | Times Cited: 58
Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases
Pei Shen, Yezhi Wang, Xiangxiang Jia, et al.
European Journal of Medicinal Chemistry (2022) Vol. 239, pp. 114551-114551
Closed Access | Times Cited: 27
Deregulated Syk inhibits differentiation and induces growth factor–independent proliferation of pre–B cells
Thomas Wossning, Sebastian Herzog, Fabian Köhler, et al.
The Journal of Experimental Medicine (2006) Vol. 203, Iss. 13, pp. 2829-2840
Open Access | Times Cited: 82
The cellular origin of mantle cell lymphoma
Francesco Bertoni, Maurilio Ponzoni
The International Journal of Biochemistry & Cell Biology (2007) Vol. 39, Iss. 10, pp. 1747-1753
Closed Access | Times Cited: 76
Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease
Luigia Lombardi, Giulia Poretti, Michela Mattioli, et al.
Genes Chromosomes and Cancer (2006) Vol. 46, Iss. 3, pp. 226-238
Closed Access | Times Cited: 70
Therapeutic prospect of Syk inhibitors
Paolo Ruzza, Barbara Biondi, Andrea Calderan
Expert Opinion on Therapeutic Patents (2009) Vol. 19, Iss. 10, pp. 1361-1376
Closed Access | Times Cited: 66
Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia
Emma Flordal Thelander, Koichi Ichimura, Martin Corcoran, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2008) Vol. 49, Iss. 3, pp. 477-487
Closed Access | Times Cited: 64
Bayesian DNA copy number analysis
Paola M. V. Rancoita, Marcus Hütter, Francesco Bertoni, et al.
BMC Bioinformatics (2009) Vol. 10, Iss. 1
Open Access | Times Cited: 62
The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies
Jan A. Burger, R. Ford
Seminars in Cancer Biology (2011) Vol. 21, Iss. 5, pp. 308-312
Closed Access | Times Cited: 57
Lessons from a decade of integrating cancer copy number alterations with gene expression profiles
Nianyuan Huang, Prediman K. Shah, Caixia Li
Briefings in Bioinformatics (2011) Vol. 13, Iss. 3, pp. 305-316
Open Access | Times Cited: 56

Scroll to top